コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 s hormone therapy for preventing or treating menopausal symptoms.
2 rse effects are enhanced in older women with menopausal symptoms.
3 ) and licorice (Glycyrrhiza spec.) to manage menopausal symptoms.
4 ng and aid in developing safer therapies for menopausal symptoms.
5 n memory and mood disorders as well as other menopausal symptoms.
6 replacement therapy (HRT) for alleviation of menopausal symptoms.
7 menopause and were treated for the relief of menopausal symptoms.
8 There was no significant impact on other menopausal symptoms.
9 red in regard to the short-term treatment of menopausal symptoms.
10 atives to using estrogen therapy in treating menopausal symptoms.
11 s the efficacy of supplements in controlling menopausal symptoms.
12 n who are prescribed HT for the treatment of menopausal symptoms.
13 ying preventive lifestyle factors related to menopausal symptoms.
14 ve increased interest in other therapies for menopausal symptoms.
15 oestrogens show promise for the treatment of menopausal symptoms.
16 and alternative medicine (CAM) therapies for menopausal symptoms.
17 questionnaire about demographic factors and menopausal symptoms.
18 ctivity and as a dietary supplement reducing menopausal symptoms.
19 erved bone mineral density, and reduction of menopausal symptoms.
20 considering hormone replacement therapy for menopausal symptoms.
21 ntries use complementary therapies to manage menopausal symptoms.
22 hese results show that women who have severe menopausal symptoms after ovarian cancer treatment can s
23 other SES measures, other health behaviors, menopausal symptoms, age at menopause, health insurance)
27 edge about reproductive health, and decrease menopausal symptoms and infertility-related distress for
28 avone-rich diets are associated with reduced menopausal symptoms and lowered risk of cancers of repro
29 t specifically target their needs related to menopausal symptoms and problems with relationships, sex
30 e-agent hormone replacement therapy to treat menopausal symptoms and reduce chronic disease risk in m
31 n overview of the questionnaires that assess menopausal symptoms and research efforts to better stand
32 When added to tamoxifen, OFS results in more menopausal symptoms and sexual dysfunction, which contri
33 dition, fatigued women were more bothered by menopausal symptoms and were somewhat more likely to hav
34 f-report measures of fatigue, sleep quality, menopausal symptoms, and coping and were administered a
37 omen and those soon after menopause who have menopausal symptoms-and other methods of treatment deliv
39 supplements, consumed by women experiencing menopausal symptoms, are suggested to have positive effe
40 opausal women that were focused on relief of menopausal symptoms, DRSP/E2 yielded significant reducti
42 body image (EST2 = .45; P = .009) and fewer menopausal symptoms (EST1 = .39; P = .007) than the cont
43 ms persist as late effects (eg, infertility, menopausal symptoms, fatigue), and there may be less fre
44 < .05) related to poorer sleep quality, more menopausal symptoms, greater use of catastrophizing as a
45 of estrogen and other hormones for treating menopausal symptoms has led to demand for other options;
46 ted with estrogen and progesterone to manage menopausal symptoms have resulted in its declining use a
47 third group (no increases) experienced more menopausal symptoms (hot flashes) than did women in the
49 ve in perimenopausal women, possibly because menopausal symptoms improve, but there is no clear benef
50 fects on sexual functioning, body image, and menopausal symptoms in BCSs with a sexual dysfunction.
51 ement therapy (HRT) is widely used to manage menopausal symptoms in women and can be comprised of an
54 y more efficacious than placebo against most menopausal symptoms, including number and intensity of h
55 istics, personal and family medical history, menopausal symptoms, information used in decision making
56 act of oncologic treatments on fertility and menopausal symptoms is often significant for patients wi
57 than placebo; its effectiveness at reducing menopausal symptoms is similar to that of oral oestradio
59 nts treated with tamoxifen plus OFS had more menopausal symptoms, lower sexual activity, and inferior
60 given available therapeutic alternatives for menopausal symptom management and chronic disease preven
61 intimacy (primary outcomes) and body image, menopausal symptoms, marital functioning, psychological
62 th breast cancer reporting treatment-induced menopausal symptoms (N=422) were randomly assigned to CB
63 gens play an important role in prevention of menopausal symptoms, osteoporosis, cancer, and heart dis
64 these two interventions combined (CBT/PE) on menopausal symptoms (primary outcome), body image, sexua
66 as associated with a substantial increase in menopausal symptoms, sexual dysfunction, and diminished
67 dering hormone therapy for the management of menopausal symptoms, such as hot flashes or vaginal dryn
69 cular disease, breast and uterine cancer and menopausal symptoms than those eating Western diets.
70 Both groups also reported improvements in menopausal symptoms that were, for the most part, not si
71 nt of women age >/= 30 years suffered severe menopausal symptoms (three- to four-fold more frequently
72 to be a potential risk factor for vasomotor menopausal symptoms (VMSs), ie, hot flushes and night sw
74 s of CAM therapies for hot flashes and other menopausal symptoms were identified; of these, 12 dealt
75 al data that young postmenopausal women with menopausal symptoms who use HT for long periods of time
76 in disease prevention; however, treatment of menopausal symptoms with low-dose estrogen remains an ap
77 of hormone therapy depend on the presence of menopausal symptoms; women without flushing had greater
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。